HIV/AIDS HAART
Early therapy more cost-effective when impact of HAART on well-being is smaller
Published in AIDS Weekly, October 10th, 2005
According to a study from the United States, "Cohort studies indicate that starting highly active antiretroviral therapy (HAART) when the CD4+ T-cell count is less than 200 cells/mcL is associated with poor outcomes. These studies have been unable to address how early HAART should be initiated, however."
"This report uses a modeling approach to compare starting HAART at a mean CD4+ T-cell count greater than 350 cells/mcL (early) versus less than 350 cells/mcL but greater than 200 cells/mcL (later).
"A Markov model tracks people with HIV...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-10-10)
More Articles from AIDS Weekly
- HIV/AIDS HAART Treatment
Viral suppression similar in patients on HAART retreatment and continuous HAART - HIV/AIDS Prognostics
Total lymphocyte counts and hemoglobin levels used to monitor HIV progression - HIV/AIDS-Associated Heart Disease
Tobacco and hypercholesterolemia most frequent ACS risk factors during HAART - HIV/AIDS-Associated Lipodystrophy
Aerobics increases HDL cholesterol in HAART-associated lipodystrophy - Health Promotion
Colorectal cancer screening underutilized in HIV patients 50+ years old - Autoimmune Disease
Key protein opens door to new treatments - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
